Patents by Inventor Douglas Michael Ackermann, JR.

Douglas Michael Ackermann, JR. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DRY EYE TREATMENTS
    Publication number: 20240173318
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Application
    Filed: January 26, 2024
    Publication date: May 30, 2024
    Inventors: Douglas Michael ACKERMANN, JR., James LOUDIN, Kenneth J. MANDELL
  • Compositions and use of varenicline for treating dry eye
    Patent number: 11911380
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Grant
    Filed: March 23, 2023
    Date of Patent: February 27, 2024
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • Compositions and use of varenicline for treating dry eye
    Patent number: 11903943
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Grant
    Filed: March 23, 2023
    Date of Patent: February 20, 2024
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • Compositions and use of varenicline for treating dry eye
    Patent number: 11903942
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Grant
    Filed: March 23, 2023
    Date of Patent: February 20, 2024
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • Compositions and use of varenicline for treating dry eye
    Patent number: 11903941
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Grant
    Filed: December 6, 2021
    Date of Patent: February 20, 2024
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • DRY EYE TREATMENTS
    Publication number: 20230226054
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Application
    Filed: March 23, 2023
    Publication date: July 20, 2023
    Inventors: Douglas Michael ACKERMANN, JR., James LOUDIN, Kenneth J. MANDELL
  • DRY EYE TREATMENTS
    Publication number: 20230226052
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Application
    Filed: March 23, 2023
    Publication date: July 20, 2023
    Inventors: Douglas Michael ACKERMANN, JR., James LOUDIN, Kenneth J. MANDELL
  • DRY EYE TREATMENTS
    Publication number: 20230226053
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Application
    Filed: March 23, 2023
    Publication date: July 20, 2023
    Inventors: Douglas Michael ACKERMANN, JR., James LOUDIN, Kenneth J. MANDELL
  • DRY EYE TREATMENTS
    Publication number: 20220233528
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Application
    Filed: December 6, 2021
    Publication date: July 28, 2022
    Inventors: Douglas Michael ACKERMANN, JR., James LOUDIN, Kenneth J. MANDELL
  • Methods of increasing lacrimal proteins
    Patent number: 11224598
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: January 18, 2022
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • DRY EYE TREATMENTS
    Publication number: 20200246336
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Application
    Filed: September 10, 2019
    Publication date: August 6, 2020
    Inventors: Douglas Michael ACKERMANN, JR., James LOUDIN, Kenneth J. MANDELL
  • Dry eye treatments
    Patent number: 10456396
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: October 29, 2019
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • Adjustable nerve electrode
    Patent number: 10456575
    Abstract: Example adjustable electrodes are described. One example adjustable electrode includes two or more contacts configured to selectively deliver high frequency alternating current (HFAC) to a nerve in an amount sufficient to produce an HFAC nerve conduction block in the nerve. The example adjustable electrode may also include a logic configured to selectively control which of the two or more contacts deliver HFAC to the nerve to control whether the nerve electrode is in a first (e.g., onset response mitigating) configuration or in a second (e.g., HFAC nerve conduction block maintenance) configuration. The electrode may be used in applications including, but not limited to, nerve block applications, and nerve stimulation applications. The electrode may be adjusted by changing attributes including, but not limited to, the number, length, orientation, distance between, surface area, and distance from a nerve of contacts to be used to deliver the HFAC.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: October 29, 2019
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Kevin Kilgore, Douglas Michael Ackermann, Jr., Niloy Bhadra, Narendra Bhadra, Joe Payer
  • ADJUSTABLE NERVE ELECTRODE
    Publication number: 20180250506
    Abstract: Example adjustable electrodes are described. One example adjustable electrode includes two or more contacts configured to selectively deliver high frequency alternating current (HFAC) to a nerve in an amount sufficient to produce an HFAC nerve conduction block in the nerve. The example adjustable electrode may also include a logic configured to selectively control which of the two or more contacts deliver HFAC to the nerve to control whether the nerve electrode is in a first (e.g., onset response mitigating) configuration or in a second (e.g., HFAC nerve conduction block maintenance) configuration. The electrode may be used in applications including, but not limited to, nerve block applications, and nerve stimulation applications. The electrode may be adjusted by changing attributes including, but not limited to, the number, length, orientation, distance between, surface area, and distance from a nerve of contacts to be used to deliver the HFAC.
    Type: Application
    Filed: May 8, 2018
    Publication date: September 6, 2018
    Inventors: Kevin Kilgore, Douglas Michael Ackermann, JR., Niloy Bhadra, Narendra Bhadra, Joe Payer
  • Adjustable nerve electrode
    Patent number: 10039917
    Abstract: Example adjustable electrodes are described. One example adjustable electrode includes two or more contacts configured to selectively deliver high frequency alternating current (HFAC) to a nerve in an amount sufficient to produce an HFAC nerve conduction block in the nerve. The example adjustable electrode may also include a logic configured to selectively control which of the two or more contacts deliver HFAC to the nerve to control whether the nerve electrode is in a first (e.g., onset response mitigating) configuration or in a second (e.g., HFAC nerve conduction block maintenance) configuration. The electrode may be used in applications including, but not limited to, nerve block applications, and nerve stimulation applications. The electrode may be adjusted by changing attributes including, but not limited to, the number, length, orientation, distance between, surface area, and distance from a nerve of contacts to be used to deliver the HFAC.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: August 7, 2018
    Assignee: Case Western Reserve University
    Inventors: Kevin Kilgore, Douglas Michael Ackermann, Jr., Niloy Bhadra, Narendra Bhadra, Joe Payer
  • Dry Eye Treatments
    Publication number: 20170239244
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Application
    Filed: February 1, 2017
    Publication date: August 24, 2017
    Applicant: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, JR., James Loudin, Kenneth J. Mandell
  • Dry eye treatments
    Patent number: 9597284
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: March 21, 2017
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • Methods of improving ocular discomfort
    Patent number: 9532944
    Abstract: Described herein are methods and pharmaceutical formulations for improving ocular discomfort.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: January 3, 2017
    Assignee: OYSTER POINT PHARMA, INC.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • Pharmaceutical formulations for treating ocular conditions
    Patent number: 9504645
    Abstract: Described herein are pharmaceutical formulations for treating ocular conditions.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: November 29, 2016
    Assignee: OYSTER POINT PHARMA, INC.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • Methods of increasing tear production
    Patent number: 9504644
    Abstract: Described herein are methods and pharmaceutical formulations for increasing tear production.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: November 29, 2016
    Assignee: OYSTER POINT PHARMA, INC.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell